Taysha Gene Therapies, Inc. (TSHA)
6.015
-0.18
(-2.98%)
USD |
NASDAQ |
Aug 26, 16:00
6.14
+0.12
(+2.08%)
After-Hours: 20:00
Taysha Gene Therapies Shareholders Equity (Quarterly) : 387.27M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 387.27M |
| March 31, 2026 | 211.94M |
| December 31, 2025 | 246.94M |
| September 30, 2025 | 218.99M |
| June 30, 2025 | 248.73M |
| March 31, 2025 | 55.06M |
| December 31, 2024 | 71.52M |
| September 30, 2024 | 88.80M |
| June 30, 2024 | 108.87M |
| March 31, 2024 | 53.85M |
| December 31, 2023 | 74.94M |
| September 30, 2023 | -49.11M |
| June 30, 2023 | -37.11M |
| Date | Value |
|---|---|
| March 31, 2023 | -14.95M |
| December 31, 2022 | 0.949M |
| September 30, 2022 | 11.13M |
| June 30, 2022 | 32.71M |
| March 31, 2022 | 50.72M |
| December 31, 2021 | 95.38M |
| September 30, 2021 | 140.39M |
| June 30, 2021 | 186.50M |
| March 31, 2021 | 222.87M |
| December 31, 2020 | 251.30M |
| September 30, 2020 | 267.64M |
| June 30, 2020 | -26.79M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Altimmune, Inc. | 474.21M |
| Protalix Biotherapeutics, Inc. | 71.40M |
| Humacyte, Inc. | 31.26M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 470.43M |
| Total Liabilities (Quarterly) | 83.17M |
| Debt to Equity Ratio | 0.1469 |
| Current Ratio | 17.76 |
| Net Debt Paydown Yield | 0.05% |